Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Could Rice Help Diabetes Patients? NutraCea Launches a Nationwide Campaign to Educate Healthcare Professionals
- Could Rice Help Diabetes Patients? NutraCea Launches a Nationwide Campaign to Educate Healthcare Professionals
- Could Rice Help Diabetes Patients? NutraCea Launches a Nationwide Campaign to Educate Healthcare Professionals
- SOLO GI(TM)(Glycemic Index*) -- A Solution to the Low-Carb Controversy
- SOLO GI(TM)(Glycemic Index*) -- A Solution to the Low-Carb Controversy
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Researchers Report Potential Healthcare Cost Savings from Using Diachrome® as a Medical Nutrition Therapy for Type 2 Diabetes
Initial results of an economic analysis conducted by Thomas Jefferson University’s Department of Health Policy indicate that use of Diachrome® as an adjunct nutritional therapy for people with type 2 diabetes, could offer significant healthcare cost savings.
- Congress Encourages Research on Chromium Picolinate and Diabetes
Bill signed into law by includes Report Language that recognizes that “chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity,” and encourages NCCAM to expand its chromium research program.
- Congress Encourages Research on Chromium Picolinate and Diabetes
Bill signed into law by includes Report Language that recognizes that “chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity,” and encourages NCCAM to expand its chromium research program.
- Congress Encourages Research on Chromium Picolinate and Diabetes
Bill signed into law by includes Report Language that recognizes that “chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity,” and encourages NCCAM to expand its chromium research program.
- Congress Encourages Research on Chromium Picolinate and Diabetes
Bill signed into law by includes Report Language that recognizes that “chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity,” and encourages NCCAM to expand its chromium research program.
- Congress Encourages Research on Chromium Picolinate and Diabetes
Bill signed into law by includes Report Language that recognizes that “chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity,” and encourages NCCAM to expand its chromium research program.
- Congress Encourages Research on Chromium Picolinate and Diabetes
Bill signed into law by includes Report Language that recognizes that “chromium picolinate can restore normal glucose metabolism by enhancing insulin sensitivity,” and encourages NCCAM to expand its chromium research program.
- Nutrition 21 Partners with Mandan, Hidatsa and Arikara Nation to Combat Epidemic of Type 2 Diabetes Among Tribal Members
Nutrition 21, Inc. and the Mandan, Hidatsa and Arikara Nation announce collaboration to conduct the first Diachrome® Physician Supervised Health Outcomes Initiative among Native Americans living with type 2 diabetes.
- Nutrition 21 Partners with Mandan, Hidatsa and Arikara Nation to Combat Epidemic of Type 2 Diabetes Among Tribal Members
Nutrition 21, Inc. and the Mandan, Hidatsa and Arikara Nation announce collaboration to conduct the first Diachrome® Physician Supervised Health Outcomes Initiative among Native Americans living with type 2 diabetes.
- Nutrition 21 Partners with Mandan, Hidatsa and Arikara Nation to Combat Epidemic of Type 2 Diabetes Among Tribal Members
Nutrition 21, Inc. and the Mandan, Hidatsa and Arikara Nation announce collaboration to conduct the first Diachrome® Physician Supervised Health Outcomes Initiative among Native Americans living with type 2 diabetes.
- FDA Approves First Qualified Health Claim for Chromium Picolinate and Risk of Type 2 Diabetes
FDA has concluded that there is credible evidence to support the following qualified health claim: “One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain.”
- FDA Approves First Qualified Health Claim for Chromium Picolinate and Risk of Type 2 Diabetes
FDA has concluded that there is credible evidence to support the following qualified health claim: “One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain.”
- FDA Approves First Qualified Health Claim for Chromium Picolinate and Risk of Type 2 Diabetes
FDA has concluded that there is credible evidence to support the following qualified health claim: “One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain.”
- FDA Approves First Qualified Health Claim for Chromium Picolinate and Risk of Type 2 Diabetes
FDA has concluded that there is credible evidence to support the following qualified health claim: “One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain.”
- Diachrome(R) Supplementation Associated with Potential Cost Savings of $52.9 Billion for People with Diabetes
economic analysis published in the August 2005 issue of the peer-reviewed journal Disease Management estimates the potential three-year cost savings that result from the decrease in HbA1C levels through the use of Diachrome, to be up to $52.9 billion for patients already diagnosed with diabetes plus a lifetime cost savings at $42 billion for newly diagnosed patients each year.
- Diachrome(R) Supplementation Associated with Potential Cost Savings of $52.9 Billion for People with Diabetes
economic analysis published in the August 2005 issue of the peer-reviewed journal Disease Management estimates the potential three-year cost savings that result from the decrease in HbA1C levels through the use of Diachrome, to be up to $52.9 billion for patients already diagnosed with diabetes plus a lifetime cost savings at $42 billion for newly diagnosed patients each year.
- Diachrome(R) Supplementation Associated with Potential Cost Savings of $52.9 Billion for People with Diabetes
economic analysis published in the August 2005 issue of the peer-reviewed journal Disease Management estimates the potential three-year cost savings that result from the decrease in HbA1C levels through the use of Diachrome, to be up to $52.9 billion for patients already diagnosed with diabetes plus a lifetime cost savings at $42 billion for newly diagnosed patients each year.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- PacificHealth Laboratories Awards Research Grant to Manchester University; Grant Will Expand Research Efforts in Weight Loss and Type II Diabetes
Company has awarded a research grant to the Gastrointestinal Sciences Research Group at The University of Manchester, Manchester, England to expand its research and product development program in weight loss and Type II diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Traditional Chinese Medicine For Diabetes Has Scientific Backing
A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment for people suffering from type 2 diabetes.
- Frutarom Signs Agreement for Exclusive Global License to Produce and Market a Unique Plant Extract to Reduce and Stabilize Glucose Levels in Blood of Diabetes and Pre-Diabetes Patients
Company has signed an exclusive global licensing agreement with D-Herb, of the NGT technological incubator in Nazareth, Israel, to produce and globally market a unique herbal extract, for the reduction and stabilization of glucose levels in the blood of diabetes and pre-diabetes patients.
- Frutarom Signs Agreement for Exclusive Global License to Produce and Market a Unique Plant Extract to Reduce and Stabilize Glucose Levels in Blood of Diabetes and Pre-Diabetes Patients
Company has signed an exclusive global licensing agreement with D-Herb, of the NGT technological incubator in Nazareth, Israel, to produce and globally market a unique herbal extract, for the reduction and stabilization of glucose levels in the blood of diabetes and pre-diabetes patients.
- Frutarom Signs Agreement for Exclusive Global License to Produce and Market a Unique Plant Extract to Reduce and Stabilize Glucose Levels in Blood of Diabetes and Pre-Diabetes Patients
Company has signed an exclusive global licensing agreement with D-Herb, of the NGT technological incubator in Nazareth, Israel, to produce and globally market a unique herbal extract, for the reduction and stabilization of glucose levels in the blood of diabetes and pre-diabetes patients.
- Sweet Success Targets Diabetic Market
Company to incorporate Integrity Nutraceuticals' Cinnulin PF(R) ingredient into its GlucaSafe(TM) beverage.
- Sweet Success Targets Diabetic Market
Company to incorporate Integrity Nutraceuticals' Cinnulin PF(R) ingredient into its GlucaSafe(TM) beverage.
- Sweet Success Targets Diabetic Market
Company to incorporate Integrity Nutraceuticals' Cinnulin PF(R) ingredient into its GlucaSafe(TM) beverage.
- GNC Introduces NutriSystem(R) Nourish(TM) Program
Company has announced a new relationship with NutriSystem, Inc. under which it is offering the NutriSystem program in 160 of its Philadelphia- and New York City-area markets and in other select GNC locations.
- GNC Introduces NutriSystem(R) Nourish(TM) Program
Company has announced a new relationship with NutriSystem, Inc. under which it is offering the NutriSystem program in 160 of its Philadelphia- and New York City-area markets and in other select GNC locations.
- GNC Introduces NutriSystem(R) Nourish(TM) Program
Company has announced a new relationship with NutriSystem, Inc. under which it is offering the NutriSystem program in 160 of its Philadelphia- and New York City-area markets and in other select GNC locations.
- Integrity Nutraceutical’s Cinnulin PF to Receive First-Ever INSIDER Scientific Excellence Award Presented at SupplySide West
Integrity Nutraceutical’s Cinnulin PF will receive the first INSIDER Scientific Excellence Award, to be presented at SupplySide West, Nov. 6 to 8 at The Venetian & The Sands Expo in Las Vegas.
- Integrity Nutraceutical’s Cinnulin PF to Receive First-Ever INSIDER Scientific Excellence Award Presented at SupplySide West
Integrity Nutraceutical’s Cinnulin PF will receive the first INSIDER Scientific Excellence Award, to be presented at SupplySide West, Nov. 6 to 8 at The Venetian & The Sands Expo in Las Vegas.
- Integrity Nutraceutical’s Cinnulin PF to Receive First-Ever INSIDER Scientific Excellence Award Presented at SupplySide West
Integrity Nutraceutical’s Cinnulin PF will receive the first INSIDER Scientific Excellence Award, to be presented at SupplySide West, Nov. 6 to 8 at The Venetian & The Sands Expo in Las Vegas.
- Integrity Nutraceutical’s Cinnulin PF to Receive First-Ever INSIDER Scientific Excellence Award Presented at SupplySide West
Integrity Nutraceutical’s Cinnulin PF will receive the first INSIDER Scientific Excellence Award, to be presented at SupplySide West, Nov. 6 to 8 at The Venetian & The Sands Expo in Las Vegas.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- New Company for “Change-The-World” Entrepreneurs™ Launches
- GMP Labs Expands Liquid Nutraceutical Capabilities
- What Parents Should Know About Kids and Supplements
- What Parents Should Know About Kids and Supplements
- Oats Beat Back Cholesterol
- Oats Beat Back Cholesterol
- Seniors: Pump Up for Strong Bones and Heart
- Seniors: Pump Up for Strong Bones and Heart
|
PURCHASE, N.Y. & BALTIMORE, Mar 21, 2005 (BUSINESS WIRE) -- Nutrition 21, Inc. (NXXI:NASDAQ) and XLHealth Corporation announced today an agreement in principle for a program that will make Diachrome(R) available to physicians for people with diabetes participating in the Center for Medicare and Medicaid (CMS) sponsored Chronic Care Improvement Program (CCIP) in Tennessee. The state ranks 2nd in the nation with persons diagnosed with diabetes, and spends approximately $3.6 billion on direct and indirectly associated health care costs. The CCIP is the first large-scale chronic care improvement initiative under the Medicare fee-for-service (FFS program). "We are excited about the opportunity to include Diachrome in this important health initiative for people with diabetes," said Patrick Hervy, chairman and chief executive officer of XLHealth. "We have seen from our past work with Nutrition 21 that Diachrome can in many cases be a valuable complement to managing beneficiaries diagnosed with diabetes, and we would like to extend these benefits to the physicians and patients who will be participating with us in our CCIP in Tennessee."
According to the Tennessee Department of Health, Bureau of Health Informatics, an estimated 417,000 state residents suffer with diabetes. XLHealth's CCIP, created by Congress as part of the 2004 Medicare Modernization Act, will begin to address the need for diabetes management by reaching out to 20,000 Medicare beneficiaries in Tennessee who are living with diabetes and heart failure.
Diachrome, a nutritional supplement specifically formulated for people with diabetes, is a patented combination of chromium as chromium picolinate and biotin. "Several years ago we entered into an alliance with XLHealth to conduct a study to validate the benefits of Diachrome as a nutritional adjunct therapy to diabetes care in large populations with diabetes," commented Gail Montgomery, president and CEO of Nutrition 21. "Today we are pleased to know that we will be working with XLHealth and directly with physicians who will be making the product available in Tennessee. As we present and publicize the new Diachrome study results at upcoming medical conferences, we expect to replicate this model of adoption with other strategic partners who are responsible for reducing the public health burden associated with the epidemic of diabetes in the United States. "
Details of the sales agreement and the use of the Diachrome(R) product are being finalized over the coming months, as XLHealth completes its contract with CMS and develops final operating protocols based on input from the Tennessee Medical Association, local physician advisory boards and the Tennessee State Medicaid office
About the Chronic Care Improvement Programs
Chronic Care Improvement Programs are an important component of the Medicare Modernization Act and demonstrate a commitment to improving and strengthening the traditional fee-for-service (FFS) Medicare program. CMS selected XLHealth to offer self-care guidance and support to 20,000 chronically ill beneficiaries in Tennessee. XLHealth will help beneficiaries manage their health, adhere to their physicians' plans of care, and assure that they seek or obtain medical care that they need to reduce their health risks.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax(R) chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome(R), which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.
About XLHealth Corporation
XLHealth (www.xlhealth.com) is a privately held company owned by a combination of founders, management and Goldman Sachs Private Equity Funds. It has been at the forefront of disease management innovations since its inception. Founded by physicians, many of whom were affiliated with Johns Hopkins, XLHealth replaces the more customary remote telephone "call-center" or direct mail support with ongoing, face-to-face meetings with patients and physicians. XLHealth also uses tight coordination of care, behavior modification, and in-depth patient profiling integrated with claims, pharmacy, and lab information to generate sophisticated, predictive modeling. The firm emphasizes preventing avoidable and expensive disease complications and hospitalizations. XLHealth was recently awarded the Disease Management Association of America's (DMAA) Recognizing Excellence Award for "Best Disease Management Program: Medicare."
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. |